Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 1.28 · gapped above the open, then crossed back over prior close. High/low 1.32 at 7:45 am ET, 1.26 at 11:30 am ET.
Caribou Biosciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On August 9, 2022, we entered into an at-the-market Open Market Sale Agreement SM ("ATM Sales Agreement") with Jefferies LLC ("Jefferies"), pursuant to which, on the terms and subject to the conditions and limitations set forth in the ATM Sales Agreement, from time to time, we could have issued and sold, through Jefferies, acting as sales agent, up to $100.0 million of our shares of common stock under the 2022 Shelf Registration Statement.”
FILING10-K0001619856-26-000008cik 0001619856
“Pfizer, related party (1) 2,487 2,487 —”
FILING10-K0001619856-26-000008cik 0001619856
“This increase is primarily due to a $2.8 million increase related to other licensees, which was partially offset by a $1.6 million decrease in revenue related to the issuance of additional shares of convertible preferred stock received as consideration to us under the Exclusive License Agreement for Veterinary Therapeutics (as amended, "Edge chRDNA License Agreement") with Edge Animal Health ("Edge") in the year ended December 31, 2024.”
FILING10-K0001619856-26-000008cik 0001619856
“Pursuant to the Leaseback Agreement, in exchange for Intellia's grant to us of an exclusive license to certain intellectual property relating to CRISPR-Cas9, including Cas9 chRDNAs, for use solely in the manufacture of our vispa-cel product candidate, we paid Intellia an upfront cash payment of $1.0 million and we will owe up to $23.0 million in potential future regulatory and sales milestones.”
FILING10-K0001619856-26-000008cik 0001619856
“Through an amendment to the Pioneer Agreement, dated December 18, 2020, Pioneer assigned the chRDNA patent family to us in exchange for an upfront payment and potential future milestones.”
FILING10-K0001619856-26-000008cik 0001619856
“For our CB-011 product candidate, an allogeneic anti-BCMA CAR-T cell therapy, we took assignment of an anti-BCMA scFv from ProMab under the ProMab Agreement.”
FILING10-K0001619856-26-000008cik 0001619856
“On January 31, 2020, we entered into a Sale and Assignment Agreement with ProMab (as amended, "ProMab Agreement") under which we purchased a humanized scFv targeting BCMA and a patent family related thereto for an upfront cash payment of $0.4 million and the potential payments of future royalties to ProMab.”
FILING10-K0001619856-26-000008cik 0001619856
“On December 15, 2016, we entered into the IMA with UC, Vienna, Dr. Charpentier, CRISPR Therapeutics AG (the exclusive licensee of Dr. Charpentier in the field of human therapeutics), ERS Genomics Ltd (the exclusive licensee of Dr. Charpentier in all fields outside human therapeutics), and Intellia, our exclusive licensee in a defined field of human therapeutics.”
FILING10-K0001619856-26-000008cik 0001619856
“We granted Pioneer an exclusive license, with the right to sublicense, to our background CRISPR intellectual property, including the CVC IP discussed below, in certain agricultural crops, specified microorganisms, a defined industrial bio field, and certain nutrition and health applications ("Pioneer Exclusive Field"), and a non-exclusive license, with the right to sublicense, to Pioneer for CRISPR in certain defined fields outside of research reagents.”
FILING10-K0001619856-26-000008cik 0001619856
“Other (expense) income consists primarily of impairment of an equity investment, interest income earned on cash and marketable securities and the change in fair value of the Memorial Sloan Kettering Cancer Center ("MSKCC") success payments liability under the now-terminated Exclusive License Agreement, dated November 13, 2020, with MSKCC (as amended, "MSKCC Agreement").”
FILING10-K0001619856-26-000008cik 0001619856
“• costs of fulfilling our contractual obligations to reimburse certain parties for costs incurred in connection with the prosecution and maintenance of licensed patent rights, including reimbursements owed to The Regents of the University of California;”
FILING10-K0001619856-26-000008cik 0001619856
“We have an exclusive license from UC and Vienna in all fields to the CVC IP, having as inventors Drs. Jennifer A. Doudna, Emmanuelle Charpentier, Martin Jinek, and Krzysztof Chylinski.”
FILING10-K0001619856-26-000008cik 0001619856
“We have an exclusive license from UC and Vienna in all fields to the CVC IP, having as inventors Drs. Jennifer A. Doudna, Emmanuelle Charpentier, Martin Jinek, and Krzysztof Chylinski.”
FILING10-K0001619856-26-000008cik 0001619856
Watchlist prices, news filtered to it, and its next report on your desk.
Caribou Biosciences, Inc. has 9 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either Caribou Biosciences, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
CRBU (Caribou Biosciences, Inc.) has 9 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: NTLA −4.21%, in healthcare.